Revium Rx. Launches Dual IPO, Resale Offerings Amid Price Disparity

TL;DR

**Revium Rx.'s dual offering is a red flag; the $1.00 resale price will cannibalize the $3.20 IPO, making this a risky bet for new money.**

AI Summary

Revium Rx. (RVRC) filed an S-1/A on October 3, 2025, detailing a dual offering strategy: a self-underwritten initial public offering (Primary Offering) of up to 1,562,500 Units at a fixed price of $3.20 per Unit, and a concurrent Resale Offering of up to 37,625,790 shares of Common Stock by Selling Stockholders at a fixed price of $1.00 per share. Each Unit in the Primary Offering consists of two shares of common stock and one warrant to purchase one share at an exercise price of $2.40. The company will not receive proceeds from the resale of Common Stock by Selling Stockholders, except for funds from the exercise of Investor Warrants. The Primary Offering aims to raise capital for the company, while the Resale Offering allows existing shareholders to monetize their holdings. The company's Common Stock currently trades on the OTCID under 'RVRC' at $0.52 per share as of October 2, 2025, and it intends to apply for quotation on the OTCQB Market. A significant risk highlighted is the potential adverse effect of the $1.00 fixed resale price on the success of the $3.20 per Unit primary offering, potentially causing substantial sales and a decline in RVRC's stock price.

Why It Matters

This S-1/A filing is critical for investors as Revium Rx. is attempting a complex dual offering with a significant price discrepancy: $3.20 per unit in its primary offering versus $1.00 per share for selling stockholders. This disparity could severely undermine the primary offering's success and dilute early investors. For employees and customers, the capital raised (or not raised) will impact the company's ability to fund operations and product development, especially in its focus areas like antimicrobial resistance. Competitively, the market will scrutinize whether Revium Rx. can successfully navigate this pricing challenge and gain traction against established pharmaceutical players.

Risk Assessment

Risk Level: high — The risk level is high due to the explicit warning in the filing: "The concurrent Resale Offering at a fixed price of $1.00 per share may adversely affect our ability to raise capital in the primary offering as the fixed resale price of $1.00 per share can be deemed by prospective investors as more attractive than the $3.20 price per unit in the primary offering." This direct competition in pricing, coupled with the potential for "substantial sales of our Common Stock by the Selling Stockholders after the effective date of this registration statement," creates significant downward pressure on the stock price and jeopardizes the primary capital raise.

Analyst Insight

Investors should exercise extreme caution and consider avoiding the primary offering at $3.20 per Unit. The availability of shares at $1.00 from selling stockholders presents a clear arbitrage opportunity for sophisticated investors, but a significant risk for those buying into the IPO. Monitor the trading activity post-effectiveness and assess if the company can justify its higher primary offering price.

Key Numbers

• $3.20 — Primary Offering Unit Price (Fixed offering price per Unit in the self-underwritten IPO)
• 1,562,500 — Units Offered in Primary Offering (Maximum number of Units to be sold by the Company)
• $1.00 — Resale Offering Share Price (Fixed price per share for Selling Stockholders until OTCQB/QX listing)
• 37,625,790 — Shares Offered in Resale Offering (Maximum number of Common Stock shares to be sold by Selling Stockholders)
• $0.52 — Last Reported Sale Price (OTC Market) (Revium Rx. Common Stock price on OTC Market as of October 2, 2025)
• $2.40 — IPO Warrant Exercise Price (Exercise price per share for warrants included in Primary Offering Units)
• 3,125,000 — Common Stock in Primary Offering Units (Total shares of Common Stock included in the 1,562,500 Units)
• 1,562,500 — Warrants in Primary Offering Units (Total warrants to purchase Common Stock included in the 1,562,500 Units)

Key Players & Entities

• Revium Rx. (company) — Registrant and issuer of securities
• Amir Avraham (person) — Principal executive offices contact
• David Aboudi, Esq. (person) — Legal counsel from Aboudi Legal Group PLLC
• Aboudi Legal Group PLLC (company) — Legal counsel for the registrant
• Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
• OTC Markets Group, Inc. (company) — Operator of the OTCID and OTCQB marketplaces
• Nevada (regulator) — State of incorporation for Revium Rx.
• Herzliya, Israel (regulator) — Location of Revium Rx.'s principal executive offices

FAQ

Risk Factors

• Dual Offering Price Discrepancy [high — financial]: The S-1/A highlights a significant risk where the fixed $1.00 resale price for 37,625,790 shares by Selling Stockholders could adversely affect the success of the Primary Offering. The Primary Offering is priced at $3.20 per Unit, which includes two shares of common stock. This substantial difference between the resale price and the primary offering price could lead to significant sales pressure on the stock, potentially causing a decline in RVRC's stock price and impacting the capital raised.
• Reliance on Future OTCQB/QX Listing [medium — financial]: The $1.00 resale price is fixed until the company's common stock is listed on the OTCQB or OTCQX Market. There is no guarantee that the company will successfully achieve this listing. Failure to obtain the listing could impact the ability of Selling Stockholders to sell their shares at the intended price and could affect investor confidence.
• Self-Underwritten Offering Risks [medium — operational]: Revium Rx. is conducting a self-underwritten offering. This means the company is responsible for marketing and selling the securities without a traditional underwriter. This structure carries risks related to the company's ability to effectively market the offering, manage the sales process, and meet its capital-raising goals.
• Limited Proceeds from Resale Offering [medium — financial]: The company will not receive any proceeds from the Resale Offering of 37,625,790 shares by Selling Stockholders, except for funds generated from the exercise of Investor Warrants. This means the capital raised for the company is solely dependent on the Primary Offering of 1,562,500 Units at $3.20 per Unit.
• Low Current Trading Price [high — market]: The company's common stock currently trades on the OTC Market at $0.52 per share as of October 2, 2025. This is significantly lower than both the Primary Offering Unit price ($3.20) and the Resale Offering share price ($1.00), indicating potential investor skepticism or a depressed market valuation.

Industry Context

The biotechnology and pharmaceutical sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on public offerings to fund clinical trials and commercialization. The current market sentiment for biotech IPOs can be volatile, influenced by clinical trial success rates, competitive pipelines, and overall economic conditions.

Regulatory Implications

As a pharmaceutical company, Revium Rx. is subject to stringent regulations from bodies like the FDA. The S-1/A filing itself is a regulatory requirement for public offerings. The company must comply with ongoing SEC reporting requirements and potentially FDA regulations related to its drug development and commercialization activities.

What Investors Should Do

1. Carefully evaluate the dual offering structure and its inherent risks.
2. Assess the company's ability to achieve its OTCQB listing.
3. Analyze the company's use of proceeds from the Primary Offering.
4. Monitor the trading volume and price action post-offering.

Key Dates

• 2025-10-03: Filing of S-1/A — Details the proposed dual offering strategy (Primary and Resale) and outlines the terms, risks, and use of proceeds.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC, typically used to update or correct information before an initial public offering (IPO). (This is the document detailing Revium Rx.'s IPO and concurrent resale offering.)

Self-Underwritten Offering

An offering where the company itself manages the sale of its securities directly to investors, rather than using an investment bank as an underwriter. (Revium Rx. is using this model for its Primary Offering, which shifts marketing and sales responsibilities to the company.)

Primary Offering

The portion of an IPO where a company sells new shares to raise capital for its operations. (This is how Revium Rx. intends to raise capital, offering Units at $3.20 each.)

Resale Offering

An offering where existing shareholders sell their shares to the public, allowing them to monetize their investment. The company does not receive proceeds from this type of offering. (Revium Rx. has a large Resale Offering component at $1.00 per share, allowing existing shareholders to sell.)

Units

A security that combines two or more different types of securities, typically sold together as a single package. (In Revium Rx.'s Primary Offering, a Unit consists of two shares of common stock and one warrant.)

Warrant

A security that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price (exercise price) before a certain expiration date. (Warrants are included in the Primary Offering Units and can be exercised at $2.40 per share.)

OTC Market

Over-the-Counter market, a decentralized market where financial instruments are traded directly between two parties without a central exchange. (Revium Rx.'s stock currently trades on the OTC Market at $0.52, and it aims to move to the OTCQB Market.)

OTCQB Market

A tier of the OTC Markets Group for early-stage and development stage companies that meet certain financial and corporate governance standards. (Revium Rx. intends to apply for quotation on this market, which is a step up from the current OTC Market.)

Year-Over-Year Comparison

This is the initial S-1/A filing for Revium Rx., detailing its first public offering. Therefore, there are no prior year financial metrics or risk factors to compare against. The filing establishes the company's current financial and operational landscape as it seeks to transition to a publicly traded entity on a recognized exchange.

Key Financial Figures

• $0.001 — ists of (i) two shares of common stock, $0.001 par value per share (the “Common
• $2.40 — is exercisable at an exercise price of $2.40 per share, will be immediately exercisa
• $3.20 — offered at the fixed offering price of $3.20 per Unit. Notwithstanding our belief th
• $0.80 — olders at a per share exercise price of $0.80 and (iii) up to 1,447,265 shares issuab
• $1.00 — rospectus at a fixed price per share of $1.00. The concurrent Resale Offering at a fi
• $0.52 — our Common Stock on the OTC Market was $0.52 per share. The Selling Stockholders and

Filing Documents

• ea0259119-s1a2_revium.htm (S-1/A) — 1785KB
• ea025911901ex10-18_revium.htm (EX-10.18) — 103KB
• ea025911901ex23-1_revium.htm (EX-23.1) — 3KB
• image_001.jpg (GRAPHIC) — 38KB
• image_002.jpg (GRAPHIC) — 128KB
• image_003.jpg (GRAPHIC) — 20KB
• image_004.jpg (GRAPHIC) — 6KB
• image_005.jpg (GRAPHIC) — 8KB
• image_006.jpg (GRAPHIC) — 10KB
• image_007.jpg (GRAPHIC) — 28KB
• image_008.jpg (GRAPHIC) — 18KB
• image_009.jpg (GRAPHIC) — 5KB
• image_010.jpg (GRAPHIC) — 20KB
• image_011.jpg (GRAPHIC) — 15KB
• image_012.jpg (GRAPHIC) — 87KB
• image_013.jpg (GRAPHIC) — 13KB
• image_014.jpg (GRAPHIC) — 14KB
• image_015.jpg (GRAPHIC) — 11KB
• ex10-18_001.jpg (GRAPHIC) — 2KB
• ex23-1_001.jpg (GRAPHIC) — 6KB
• ex23-1_002.jpg (GRAPHIC) — 79KB
• 0001213900-25-096094.txt ( ) — 2595KB

Risk Factors

Risk Factors 5 Special Note About Forward-Looking Statements 30

Use of Proceeds

Use of Proceeds 31 Determination of the Offering Price 32 Capitalization 33

Dilution

Dilution 34 Market Price of and Dividends on the Company’s Common Equity 35 Management’s Discussion and Analysis of Financial Condition and Results of Operations of Revium Rx 36 Description of Business 47 Management 106

Executive Compensation

Executive Compensation 109

Security Ownership of Certain Beneficial Owners & Management

Security Ownership of Certain Beneficial Owners & Management 113 Certain Relationships and Related Transactions 114

Description of Securities

Description of Securities 115 Shares Eligible for Future Sale 117 Legal Matters 117 Experts 117 Where you Can Find More Information

Financial Statements of Revium Rx

Financial Statements of Revium Rx. F-1 i ABOUT THIS PROSPECTUS This Prospectus is part of a registration statement on Form S-1 that we filed with the U.S. Securities and Exchange Commission (the “SEC”). You should read this Prospectus and any documents that we incorporate by reference in this Prospectus before making an investment decision. You should rely only on the information contained in or incorporated by reference into this Prospectus. We have not authorized anyone to provide you with information different from that contained in this Prospectus or incorporated by reference herein. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this Prospectus. You must not rely on any unauthorized information or representation. This Prospectus is an offer by the Company to sell only the securities offered hereby but only under circumstances and in jurisdictions where it is lawful to do so. The distribution of this Prospectus and the issuance of the securities in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this Prospectus must inform themselves about, and observe any restrictions relating to, the issuance of the securities and the distribution of this prospectus outside the United States. This Prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, the securities offered by this Prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. Our business, financial condition, results of operations and prospects may have changed since those dates. Unless otherwise indicated, information contained in this Prospectus or incorporated by reference herein concerning our industry and the markets in which we operate is based on information from independent industry and research organizations, other

View Full Filing

View this S-1/A filing on SEC EDGAR